PGD is a genetic test on cells removed from embryos, to help select the best embryo(s) to achieve pregnancy or to avoid a genetic disease for which a couple is at risk
Laboratory Institute of Mehr one of the key factors of health monitoring , diagnosis and control of treatment.
In this laboratory, in collaboration with professionals and experts embryology laboratory
Hedyeh Mehr National Magazine started its activities in the field of information, research, education and news in March 2011
Preimplantation genetic diagnosis involves testing the early embryo after in vitro fertilisation. One or two cells (blastomeres) are removed at biopsy from the preimplantation embryo at the 6-10 cell stage (day 3 of development), thus allowing replacement into the uterus of unaffected embryos.
Preimplantation genetic diagnosis can be offered for three major categories of disease. Firstly, it can be used to determine the sex of the embryo for sex linked disorders where the specific genetic defect at a molecular level is unknown, highly variable, or unsuitable for testing on single cells—for example Duchenne muscular dystrophy.1 Secondly, it can be used to identify single gene defects such as cystic fibrosis, where the molecular abnormality is testable with molecular techniques after polymerase chain reaction (PCR) amplification of DNA extracted from single cells.2 Thirdly, it can be used in chromosomal disorders, where fluorescence in situ hybridisation has been developed to detect a variety of chromosomal rearrangements, including translocations, inversions, and chromosome deletions.3 Some potential parents who carry a chromosomal rearrangement may never have achieved a viable pregnancy before requesting preimplantation genetic diagnosis if each previous conception resulted in a chromosomally unbalanced embryo which miscarried spontaneously.
